

NIPPON CHEMIPHAR TO GET MARKETING AUTHORIZATION FOR MUCOSOLVAN[®] EXPECTORANTS IN JAPAN

Nippon Chemiphar Co., Ltd.
(TSE: 4539)

October 1, 2026

Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Kazushiro Yamaguchi; hereinafter “Chemiphar”) has announced that it will acquire the marketing authorization for Mucosolvan[®] expectorant products from Teijin Pharma Limited (Head Office: Chiyoda-ku, Tokyo; President: Masaki Taneda).

Following the completion of the necessary procedures involving the Ministry of Health, Labour and Welfare, Chemiphar plans to accede to the marketing authorization for the products on January 1, 2027.

On the same date, Chemiphar will start selling the products, while collecting relevant information that it will provide to medical institutions.

The impact of the acquisition already has been reflected in the forecast for FY2026, announced on May 15, 2026.

Applicable Items

Therapeutic Category	Product Name
Expectorants	Mucosolvan [®] Tablets 15 mg
	Mucosolvan [®] L Tablets 45 mg
	Mucosolvan [®] Oral Solution 0.75%
	Mucosolvan [®] Syrup for Pediatric Use 0.3%
	Mucosolvan [®] DS for Pediatric Use 1.5%

For further information contact:

Corporate Planning Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp